Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Patent: 9,283,192

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,283,192
Title:Delayed prolonged drug delivery
Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a prolonged manner at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping, shortly before waking and continues to administer the drug during the early waking hours. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a prolonged release of drug.
Inventor(s): Mullen; Alexander (Glasgow, GB), Stevens; Howard (Glasgow, GB), Eccleston; Sarah (Scotstoun, GB)
Assignee: UNIVERSITY OF STRATHCLYDE (Glasgow, GB)
Application Number:13/582,926
Patent Claims:see list of patent claims

Details for Patent 9,283,192

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial UNIVERSITY OF STRATHCLYDE (Glasgow, GB) 2030-03-05 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial UNIVERSITY OF STRATHCLYDE (Glasgow, GB) 2030-03-05 RX Orphan search
Genentech TNKASE tenecteplase VIAL 103909 001 2000-06-02   Start Trial UNIVERSITY OF STRATHCLYDE (Glasgow, GB) 2030-03-05 RX search
Ekr Therap RETAVASE reteplase VIAL 103786 001 1998-05-06   Start Trial UNIVERSITY OF STRATHCLYDE (Glasgow, GB) 2030-03-05 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial UNIVERSITY OF STRATHCLYDE (Glasgow, GB) 2030-03-05 RX Orphan search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial UNIVERSITY OF STRATHCLYDE (Glasgow, GB) 2030-03-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
Medtronic
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.